ImmunoCellular Therapeutics Issued New Patent for Diagnosis and Treatment of Ovarian Cancer and Multiple Myeloma

LOS ANGELES--(BUSINESS WIRE)-- ImmunoCellular Therapeutics, Ltd. (“ImmunoCellular” or the “Company”) (OTCBB: IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced the issuance of a patent in France and the United Kingdom relating to the treatment and detection of multiple myeloma and ovarian cancer. Patent No. 1,204,683, entitled "Ovarian cancer cells and myeloma cell surface glycoproteins, antibodies thereto, and uses therof," covers aspects of the Company’s monoclonal antibody ICT-69, which targets human multiple myeloma and ovarian cancer cells. ICT-69 is already covered in the United States and this patent expands coverage of Company's issued patent portfolio to nine.

“We are actively extending our intellectual property protection for the treatment and detection of cancers,” said Manish Singh, Ph.D. president and CEO of ImmunoCellular Therapeutics. “Strengthening our patent portfolio will support the developmental efforts surrounding our technology platforms and enhance our ability to license or partner these platforms.”

About ImmunoCellular Therapeutics, Ltd.

ImmunoCellular Therapeutics is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about the Company, please visit www.imuc.com.

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the risk that the patents issued for ICT-69 may not provide commercially significant protection for that product candidate; and the risk that the Company will be unsuccessful in securing licensees or strategic partners that will be necessary to develop and commercialize ICT-69 on attractive terms or at all. Additional risks and uncertainties are described in the Company's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.



CONTACT:

For ImmunoCellular Therapeutics, Ltd.
CEOcast, Inc.
James Young, 212-732-4300
Investor Relations
[email protected]

KEYWORDS:   United Kingdom  United States  Europe  North America  California  France

INDUSTRY KEYWORDS:   Health  Biotechnology  Clinical Trials  Oncology  Pharmaceutical

MEDIA:

Suggested Articles

NASH leaders weigh in on the need for a drug for the disease and the challenges in getting it to patients.

The $210 million fund began life by leading a $17 million series A round in Quellis Biosciences.

The nine-story building will house Amgen’s Bay Area employees when it opens early in 2022.